Skip to content

Elise K. Burkhartzmeyer

Usona Institute

2 papers in the library · 18 citations · publishing 2024-2026

Papers

Psychedelic-like Activity of Norpsilocin Analogues

ACS Chemical Neuroscience January 8, 2024 Alexander M. Sherwood, Elise K. Burkhartzmeyer, Samuel E. Williamson et al. 18 citations

Psilocin, a metabolite of psilocybin, produces psychedelic effects in vivo, while norpsilocin, which differs by a single N-methyl group, does not. To explore this, eight norpsilocin derivatives with varied secondary amine groups were synthesized to increase lipophilicity and brain permeability. In mouse head-twitch response (HTR) studies, extending norpsilocin's N-methyl group to an N-ethyl group (4-HO-NET) produced psilocin-like activity (ED50 = 1.4 mg/kg). N-allyl, N-propyl, N-isopropyl, and N-benzyl derivatives also induced HTRs (ED50 = 1.1–3.2 mg/kg), with variable maximum effects (26–77 total HTR events). Bulky tert-butyl or cyclohexyl groups did not elicit psilocin-like HTRs. In vitro, these tryptamines interacted with multiple serotonin receptor subtypes and other CNS proteins.

Synthesis and Characterization of Psilocybin Metabolites and Deuterated Analogs

ACS Chemical Neuroscience March 3, 2026 Samuel E. Williamson, Elise K. Burkhartzmeyer, Michael T. Faley et al.

To support ongoing clinical trials, the major human metabolites of psilocybin—psilocin-O-glucuronide and 4-hydroxyindole-3-acetic acid (4-HIAA)—along with putative minor metabolites and several deuterium-labeled derivatives, were synthesized on a preparative scale. When assayed for engagement at seven serotonin receptor subtypes using a BRET-based binding assay, only psilocin exhibited any discernible binding. Given the high cost and challenging preparation of these compounds, the work provides a comprehensive guide for researchers to access these resources, advancing both basic and clinical research with psilocybin and its metabolites.